<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Omaveloxolone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Omaveloxolone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Omaveloxolone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="140907" href="/d/html/140907.html" rel="external">see "Omaveloxolone: Drug information"</a> and <a class="drug drug_patient" data-topicid="140936" href="/d/html/140936.html" rel="external">see "Omaveloxolone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57957667"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Skyclarys</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F57922535"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Nuclear Factor Erythroid 2-Related Factor 2 Activator</span></li></ul></div>
<div class="block dop drugH1Div" id="F58032429"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f83346ad-961b-40e4-bfc1-49a6174413ed">Friedreich ataxia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Friedreich ataxia:</b> Adolescents ≥16 years: Oral: 150 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33068037','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33068037','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Signs of decreasing cardiac function which may include new or worsening fluid overload (eg, ≥1.4 kg [3 lb] in 1 day or ≥2.3 kg [5 lb] in 1 week) and/or elevated B-type natriuretic peptide</i>: Promptly evaluate cardiac function and B-type natriuretic peptide (if not already obtained) and manage appropriately; management of fluid overload and heart failure may require discontinuation of therapy.</p></div>
<div class="block dorp drugH1Div" id="F58032432"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F58032433"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥16 years: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate impairment (Child-Pugh class B): 100 mg once daily; may decrease to 50 mg once daily if adverse reactions occur.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment (Child-Pugh class C): Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">ALT and/or AST &gt;5 times ULN, or ALT and/or AST &gt;3 times ULN with evidence of hepatic dysfunction (eg, elevated bilirubin): Immediately discontinue and repeat LFTs. If elevated transaminases stabilize or resolve, may reinitiate therapy with increased monitoring.</p></div>
<div class="block doa drugH1Div" id="F58006196"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="140907" href="/d/html/140907.html" rel="external">see "Omaveloxolone: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f83346ad-961b-40e4-bfc1-49a6174413ed">Friedreich ataxia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Friedreich ataxia: Oral:</b> 150 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33068037','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33068037','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose:</b> If a dose is missed, take the next dose at its scheduled time the next day; do not double the dose to make up for a missed dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58006198"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F58006199"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Pugh class B): 100 mg once daily; may decrease to 50 mg once daily if adverse reactions occur.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">ALT and/or AST &gt;5 times ULN, or ALT and/or AST &gt;3 times ULN with evidence of hepatic dysfunction (eg, elevated bilirubin): Immediately discontinue and repeat LFTs. If elevated transaminases stabilize or resolve, may reinitiate therapy with increased monitoring.</p></div>
<div class="block arsc drugH1Div" id="F58571425"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Transaminase elevation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased serum alanine aminotransferase</b> (ALT) and <b>increased serum aspartate aminotransferase </b>(AST) have been reported with omaveloxolone. Transaminase elevation was asymptomatic and reversible with discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33068037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33068037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to the pharmacologic action; activation of nuclear factor erythroid 2-related factor (Nrf2) induces aminotransferase genes and increases serum activity of ALT and AST (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33068037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33068037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; maximum increases in ALT and AST typically occur within 12 weeks of initiation of therapy.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F57935993"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased LDL cholesterol (16%), increased serum cholesterol (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (29%), decreased appetite (12%), diarrhea (20%), nausea (33%), vomiting (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≤37%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Alanine Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-alanine-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-alanine-aminotransferase')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Serum Alanine Aminotransferase</span>, increased serum aspartate aminotransferase (≤37%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Aspartate Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-aspartate-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-aspartate-aminotransferase')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Serum Aspartate Aminotransferase</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Alanine Aminotransferase" frame="border" id="lexi-content-increased-serum-alanine-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Omaveloxolone: Adverse Reaction: Increased Serum Alanine Aminotransferase</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Omaveloxolone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Omaveloxolone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Combined incidence with increased serum aspartate aminotransferase</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Aspartate Aminotransferase" frame="border" id="lexi-content-increased-serum-aspartate-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Omaveloxolone: Adverse Reaction: Increased Serum Aspartate Aminotransferase</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Omaveloxolone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Omaveloxolone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Combined incidence with increased serum alanine aminotransferase</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (24%), headache (37%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (13%), muscle spasm (14%), musculoskeletal pain (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oropharyngeal pain (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased HDL cholesterol (6%)</p></div>
<div class="block coi drugH1Div" id="F57917977"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58006176"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac effects: B-type natriuretic peptide increases may occur during therapy and may indicate cardiac failure. Cardiac failure and cardiomyopathy may also occur with Friedreich ataxia. Associated signs/symptoms of cardiac failure–associated fluid overload include sudden weight gain (eg, ≥1.4 kg [3 lb] in 1 day or ≥2.3 kg [5 lb] in 1 week), palpitations, peripheral edema, and shortness of breath.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid abnormalities: Increases in cholesterol and LDL and decreases in HDL may occur during therapy. Cholesterol increases typically occur within 2 weeks of initiation of therapy and return to baseline within 4 weeks of therapy discontinuation. At 48 weeks of therapy, a mean LDL increase of 23.5 mg/dL and a mean HDL decrease of 5.3 mg/dL have been measured.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with preexisting liver impairment.</p></div>
<div class="block foc drugH1Div" id="F57957668"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Skyclarys: 50 mg [contains fd&amp;c blue #1 (brilliant blue)]</p></div>
<div class="block geq drugH1Div" id="F57957666"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57989949"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Skyclarys Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $411.11</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F58032434"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach ≥1 hour before eating. Swallow capsules whole; do not open, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose</i>: If a dose is missed, administer the next dose at its scheduled time the next day; do not double the dose.</p></div>
<div class="block adm drugH1Div" id="F58006202"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer on an empty stomach ≥1 hour prior to eating. Swallow capsules whole; do not open, crush, or chew.</p></div>
<div class="block sts drugH1Div" id="F58006179"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F57922536"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of Friedreich ataxia (FDA approved in ages ≥16 years and adults).</p></div>
<div class="block mst drugH1Div" id="F58006172"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Omaveloxolone may be confused with oxandrolone.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57985066"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (minor), CYP2J2 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> BCRP/ABCG2, CYP2C8 (weak), CYP3A4 (weak), OATP1B1/1B3 (SLCO1B1/1B3)</p></div>
<div class="block dri drugH1Div" id="F57985063"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: BCRP/ABCG2 Inducers may decrease the serum concentration of Cladribine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Omaveloxolone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Omaveloxolone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Omaveloxolone. Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 100 mg daily and monitor closely for adverse reactions. If adverse reactions occur, decrease omaveloxolone to 50 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Omaveloxolone. Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 50 mg daily and monitor closely for adverse reactions. Discontinue coadministration if adverse reactions occur.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Omaveloxolone may decrease the serum concentration of Hormonal Contraceptives. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: OATP1B1/1B3 (SLCO1B1/1B3) Inducers may decrease the serum concentration of Zavegepant. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F58006178"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">C<sub>max</sub> and AUC are increased (350% and 15%, respectively) with administration with a high-fat meal (800 to 1,000 calories; ~150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively) compared to fasted conditions. Grapefruit and grapefruit juice increases exposure. Management: Administer on an empty stomach ≥1 hour prior to eating; avoid grapefruit and grapefruit juice during therapy.</p></div>
<div class="block dic drugH1Div" id="F58006201"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer on an empty stomach ≥1 hour prior to eating. Avoid grapefruit and grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F58006173"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Omaveloxolone may decrease the efficacy of hormonal contraceptives. Patients taking hormonal contraceptives should use an alternative method (eg, nonhormonal IUD) or a concomitant nonhormonal contraceptive (eg, condom) during treatment and for 28 days after the last dose of omaveloxolone. Consult drug interactions database for more detailed information specific to use of omaveloxolone and specific contraceptives.</p></div>
<div class="block pri drugH1Div" id="F58006174"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies, in utero exposure to omaveloxolone may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F58032435"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ALT, AST, total bilirubin (baseline, monthly for first 3 months, periodically thereafter; if therapy is interrupted due to elevated ALT, AST, and/or total bilirubin and reinitiated, increase frequency of monitoring as clinically appropriate), lipid panel (baseline, during therapy as clinically appropriate), B-type natriuretic peptide (baseline, if signs or symptoms of decreased cardiac function). Monitor for signs/symptoms of cardiac dysfunction including fluid overload (eg, sudden weight gain [eg, ≥1.4 kg (3 lb) in 1 day or ≥2.3 kg (5 lb) in 1 week], palpitations, peripheral edema, shortness of breath).</p></div>
<div class="block pha drugH1Div" id="F58006180"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Omaveloxolone activates Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways, which are involved in the cellular response to oxidative stress; in vitro, omaveloxolone restores mitochondrial function in fibroblasts obtained from patients with Friedreich ataxia (Abeti 2018; Lynch 2021; manufacturer's labeling).</p></div>
<div class="block phk drugH1Div" id="F58006186"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: C<sub>max</sub> and AUC are increased (350% and 15%, respectively) with administration with a high-fat meal (800 to 1,000 calories; ~150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively) compared to fasted conditions.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 7,361 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 97%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily metabolized via CYP3A with minor metabolism via CYP2C8 and CYP2J2.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 57 hours (range: 32 to 90 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: 7 to 14 hours; range: 1 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 92%; urine: 0.1%.</p></div>
<div class="block phksp drugH1Div" id="F58006194"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function: Moderate and severe hepatic impairment (Child-Pugh class B and C): Clearance is reduced, resulting in increased AUC and C<sub>max</sub> (increased by 1.65-fold and 1.83-fold, respectively, in moderate hepatic impairment; AUC variably increased by up to 2.17-fold in severe hepatic impairment). Dosage reduction is recommended.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30065630">
<a name="30065630"></a>Abeti R, Baccaro A, Esteras N, Giunti P. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich's ataxia models. <i>Front Cell</i>
<i>Neurosci</i>. 2018;12:188. doi:10.3389/fncel.2018.00188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omaveloxolone-pediatric-drug-information/abstract-text/30065630/pubmed" id="30065630" target="_blank">30065630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33068037">
<a name="33068037"></a>Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study). <i>Ann Neurol</i>. 2021;89(2):212-225. doi:10.1002/ana.25934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omaveloxolone-pediatric-drug-information/abstract-text/33068037/pubmed" id="33068037" target="_blank">33068037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference">
                  Skyclarys (omaveloxolone) [prescribing information]. Plano, TX: Reata Pharmaceuticals Inc; February 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 140921 Version 20.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
